{"transactions":[{"id":4622458,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":52348,"kind":"person","name":"Calvin Sandra","position":1,"cik":"0001882909","reported_name":"Calvin Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF ACCOUNTING OFFICER"}}],"security":"Employee stock option (right to buy)","published_at":"2026-09-18T01:29:21.000Z","date":"2026-09-15","kind":"exercise","planned":true,"acquired":false,"shares":1625,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"One-fourth of the shares subject to the stock option vested and become exercisable on the first anniversary of January 31, 2025, and the remaining shares vest in 36 equal monthly installments thereafter."}],"balance_after":17875,"derivative":{"exercise_price":20.46,"expiration_date":"2035-01-31","underlying":"Common Stock","underlying_shares":1625},"source":{"system":"sec-edgar","filing":"0001882909-26-000004","document":"form4-09182026_010916.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1882909/000188290926000004/form4-09182026_010916.xml","form_type":"4"}},{"id":4622457,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":52348,"kind":"person","name":"Calvin Sandra","position":1,"cik":"0001882909","reported_name":"Calvin Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF ACCOUNTING OFFICER"}}],"security":"Employee stock option (right to buy)","published_at":"2026-09-18T01:29:21.000Z","date":"2026-09-15","kind":"exercise","planned":true,"acquired":false,"shares":1250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"One-fourth of the shares subject to the stock option vested and became exercisable on the first anniversary of January 31, 2023, and the remaining shares vest in 36 equal monthly installments thereafter."}],"balance_after":3750,"derivative":{"exercise_price":22.4,"expiration_date":"2033-01-31","underlying":"Common Stock","underlying_shares":1250},"source":{"system":"sec-edgar","filing":"0001882909-26-000004","document":"form4-09182026_010916.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1882909/000188290926000004/form4-09182026_010916.xml","form_type":"4"}},{"id":4622456,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":52348,"kind":"person","name":"Calvin Sandra","position":1,"cik":"0001882909","reported_name":"Calvin Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF ACCOUNTING OFFICER"}}],"security":"Employee stock option (right to buy)","published_at":"2026-09-18T01:29:21.000Z","date":"2026-09-15","kind":"exercise","planned":true,"acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":27.5,"expiration_date":"2032-01-31","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001882909-26-000004","document":"form4-09182026_010916.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1882909/000188290926000004/form4-09182026_010916.xml","form_type":"4"}},{"id":4622455,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":52348,"kind":"person","name":"Calvin Sandra","position":1,"cik":"0001882909","reported_name":"Calvin Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF ACCOUNTING OFFICER"}}],"security":"Common Stock","published_at":"2026-09-18T01:29:21.000Z","date":"2026-09-15","kind":"sale","planned":true,"acquired":false,"shares":300,"price":63.6633,"value":19098.99,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The weighted average sale price for the transaction reported was $63.6633, and the range of prices were between $63.64 and $63.71. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided."}],"balance_after":42353,"source":{"system":"sec-edgar","filing":"0001882909-26-000004","document":"form4-09182026_010916.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1882909/000188290926000004/form4-09182026_010916.xml","form_type":"4"}},{"id":4622454,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":52348,"kind":"person","name":"Calvin Sandra","position":1,"cik":"0001882909","reported_name":"Calvin Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF ACCOUNTING OFFICER"}}],"security":"Common Stock","published_at":"2026-09-18T01:29:21.000Z","date":"2026-09-15","kind":"sale","planned":true,"acquired":false,"shares":800,"price":62.8481,"value":50278.48,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The weighted average sale price for the transaction reported was $62.8481, and the range of prices were between $62.62 and $63.19. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided."}],"balance_after":42653,"source":{"system":"sec-edgar","filing":"0001882909-26-000004","document":"form4-09182026_010916.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1882909/000188290926000004/form4-09182026_010916.xml","form_type":"4"}},{"id":4622453,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":52348,"kind":"person","name":"Calvin Sandra","position":1,"cik":"0001882909","reported_name":"Calvin Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF ACCOUNTING OFFICER"}}],"security":"Common Stock","published_at":"2026-09-18T01:29:21.000Z","date":"2026-09-15","kind":"sale","planned":true,"acquired":false,"shares":4275,"price":62.135,"value":265627.125,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $62.135, and the range of prices were between $61.53 and $62.51. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided."}],"balance_after":43453,"source":{"system":"sec-edgar","filing":"0001882909-26-000004","document":"form4-09182026_010916.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1882909/000188290926000004/form4-09182026_010916.xml","form_type":"4"}},{"id":4622452,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":52348,"kind":"person","name":"Calvin Sandra","position":1,"cik":"0001882909","reported_name":"Calvin Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF ACCOUNTING OFFICER"}}],"security":"Common Stock","published_at":"2026-09-18T01:29:21.000Z","date":"2026-09-15","kind":"exercise","planned":true,"acquired":true,"shares":1625,"price":20.46,"value":33247.5,"ownership":{"direct":true},"balance_after":47728,"source":{"system":"sec-edgar","filing":"0001882909-26-000004","document":"form4-09182026_010916.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1882909/000188290926000004/form4-09182026_010916.xml","form_type":"4"}},{"id":4622451,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":52348,"kind":"person","name":"Calvin Sandra","position":1,"cik":"0001882909","reported_name":"Calvin Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF ACCOUNTING OFFICER"}}],"security":"Common Stock","published_at":"2026-09-18T01:29:21.000Z","date":"2026-09-15","kind":"exercise","planned":true,"acquired":true,"shares":1250,"price":22.4,"value":28000.0,"ownership":{"direct":true},"balance_after":46103,"source":{"system":"sec-edgar","filing":"0001882909-26-000004","document":"form4-09182026_010916.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1882909/000188290926000004/form4-09182026_010916.xml","form_type":"4"}},{"id":4622450,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":52348,"kind":"person","name":"Calvin Sandra","position":1,"cik":"0001882909","reported_name":"Calvin Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF ACCOUNTING OFFICER"}}],"security":"Common Stock","published_at":"2026-09-18T01:29:21.000Z","date":"2026-09-15","kind":"exercise","planned":true,"acquired":true,"shares":2500,"price":27.5,"value":68750.0,"ownership":{"direct":true},"balance_after":44853,"source":{"system":"sec-edgar","filing":"0001882909-26-000004","document":"form4-09182026_010916.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1882909/000188290926000004/form4-09182026_010916.xml","form_type":"4"}},{"id":807651,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":52348,"kind":"person","name":"Calvin Sandra","position":1,"cik":"0001882909","reported_name":"Calvin Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF ACCOUNTING OFFICER"}}],"security":"Employee stock option (right to buy)","published_at":"2026-04-16T20:05:10.000Z","date":"2026-04-14","kind":"exercise","planned":true,"acquired":false,"shares":6500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"One-fourth of the shares subject to the stock option vested and become exercisable on the first anniversary of January 31, 2025, and the remaining shares vest in 36 equal monthly installments thereafter."}],"balance_after":19500,"derivative":{"exercise_price":20.46,"expiration_date":"2035-01-31","underlying":"Common Stock","underlying_shares":6500},"source":{"system":"sec-edgar","filing":"0001882909-26-000003","document":"form4-04162026_040403.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1882909/000188290926000003/form4-04162026_040403.xml","form_type":"4"}},{"id":807650,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":52348,"kind":"person","name":"Calvin Sandra","position":1,"cik":"0001882909","reported_name":"Calvin Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF ACCOUNTING OFFICER"}}],"security":"Employee stock option (right to buy)","published_at":"2026-04-16T20:05:10.000Z","date":"2026-04-14","kind":"exercise","planned":true,"acquired":false,"shares":6250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One-fourth of the shares subject to the stock option vested and became exercisable on the first anniversary of January 31, 2024, and the remaining shares vest in 36 equal monthly installments thereafter."}],"balance_after":12500,"derivative":{"exercise_price":8.93,"expiration_date":"2034-01-31","underlying":"Common Stock","underlying_shares":6250},"source":{"system":"sec-edgar","filing":"0001882909-26-000003","document":"form4-04162026_040403.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1882909/000188290926000003/form4-04162026_040403.xml","form_type":"4"}},{"id":807649,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":52348,"kind":"person","name":"Calvin Sandra","position":1,"cik":"0001882909","reported_name":"Calvin Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF ACCOUNTING OFFICER"}}],"security":"Employee stock option (right to buy)","published_at":"2026-04-16T20:05:10.000Z","date":"2026-04-14","kind":"exercise","planned":true,"acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One-fourth of the shares subject to the stock option vested and became exercisable on the first anniversary of January 31, 2023, and the remaining shares vest in 36 equal monthly installments thereafter."}],"balance_after":5000,"derivative":{"exercise_price":22.4,"expiration_date":"2033-01-31","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001882909-26-000003","document":"form4-04162026_040403.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1882909/000188290926000003/form4-04162026_040403.xml","form_type":"4"}},{"id":807648,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":52348,"kind":"person","name":"Calvin Sandra","position":1,"cik":"0001882909","reported_name":"Calvin Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF ACCOUNTING OFFICER"}}],"security":"Common Stock","published_at":"2026-04-16T20:05:10.000Z","date":"2026-04-14","kind":"sale","planned":true,"acquired":false,"shares":21977,"price":41.07,"value":902595.39,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was made pursuant to a written plan adopted on June 10, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."}],"balance_after":42353,"source":{"system":"sec-edgar","filing":"0001882909-26-000003","document":"form4-04162026_040403.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1882909/000188290926000003/form4-04162026_040403.xml","form_type":"4"}},{"id":807647,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":52348,"kind":"person","name":"Calvin Sandra","position":1,"cik":"0001882909","reported_name":"Calvin Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF ACCOUNTING OFFICER"}}],"security":"Common Stock","published_at":"2026-04-16T20:05:10.000Z","date":"2026-04-14","kind":"exercise","planned":true,"acquired":true,"shares":6500,"price":20.46,"value":132990.0,"ownership":{"direct":true},"balance_after":64330,"source":{"system":"sec-edgar","filing":"0001882909-26-000003","document":"form4-04162026_040403.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1882909/000188290926000003/form4-04162026_040403.xml","form_type":"4"}},{"id":807646,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":52348,"kind":"person","name":"Calvin Sandra","position":1,"cik":"0001882909","reported_name":"Calvin Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF ACCOUNTING OFFICER"}}],"security":"Common Stock","published_at":"2026-04-16T20:05:10.000Z","date":"2026-04-14","kind":"exercise","planned":true,"acquired":true,"shares":6250,"price":8.93,"value":55812.5,"ownership":{"direct":true},"balance_after":57830,"source":{"system":"sec-edgar","filing":"0001882909-26-000003","document":"form4-04162026_040403.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1882909/000188290926000003/form4-04162026_040403.xml","form_type":"4"}},{"id":807645,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":52348,"kind":"person","name":"Calvin Sandra","position":1,"cik":"0001882909","reported_name":"Calvin Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF ACCOUNTING OFFICER"}}],"security":"Common Stock","published_at":"2026-04-16T20:05:10.000Z","date":"2026-04-14","kind":"exercise","planned":true,"acquired":true,"shares":2500,"price":22.4,"value":56000.0,"ownership":{"direct":true},"balance_after":51580,"source":{"system":"sec-edgar","filing":"0001882909-26-000003","document":"form4-04162026_040403.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1882909/000188290926000003/form4-04162026_040403.xml","form_type":"4"}},{"id":923138,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":52348,"kind":"person","name":"Calvin Sandra","position":1,"cik":"0001882909","reported_name":"Calvin Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF ACCOUNTING OFFICER"}}],"security":"Employee stock option (right to buy)","published_at":"2026-02-04T02:30:07.000Z","date":"2026-01-31","kind":"grant","planned":false,"acquired":true,"shares":20160,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter."}],"balance_after":20160,"derivative":{"exercise_price":33.095,"expiration_date":"2036-01-31","underlying":"Common Stock","underlying_shares":20160},"source":{"system":"sec-edgar","filing":"0001882909-26-000001","document":"form4-02032026_090201.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1882909/000188290926000001/form4-02032026_090201.xml","form_type":"4"}},{"id":923137,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":52348,"kind":"person","name":"Calvin Sandra","position":1,"cik":"0001882909","reported_name":"Calvin Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF ACCOUNTING OFFICER"}}],"security":"Common Stock","published_at":"2026-02-04T02:30:07.000Z","date":"2026-02-03","kind":"sale","planned":false,"acquired":false,"shares":4333,"price":32.12,"value":139175.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a \"sell to cover\" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person."}],"balance_after":49080,"source":{"system":"sec-edgar","filing":"0001882909-26-000001","document":"form4-02032026_090201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1882909/000188290926000001/form4-02032026_090201.xml","form_type":"4"}},{"id":923136,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":52348,"kind":"person","name":"Calvin Sandra","position":1,"cik":"0001882909","reported_name":"Calvin Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF ACCOUNTING OFFICER"}}],"security":"Common Stock","published_at":"2026-02-04T02:30:07.000Z","date":"2026-01-31","kind":"grant","planned":false,"acquired":true,"shares":15180,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer."}],"balance_after":53413,"source":{"system":"sec-edgar","filing":"0001882909-26-000001","document":"form4-02032026_090201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1882909/000188290926000001/form4-02032026_090201.xml","form_type":"4"}},{"id":959020,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":52348,"kind":"person","name":"Calvin Sandra","position":1,"cik":"0001882909","reported_name":"Calvin Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF ACCOUNTING OFFICER"}}],"security":"Common Stock","published_at":"2025-12-30T01:59:12.000Z","date":"2025-12-24","kind":"sale","planned":true,"acquired":false,"shares":7402,"price":40,"value":296080.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was made pursuant to a written plan adopted on June 10, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."}],"balance_after":38233,"source":{"system":"sec-edgar","filing":"0001882909-25-000008","document":"form4-12302025_011208.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1882909/000188290925000008/form4-12302025_011208.xml","form_type":"4"}},{"id":968337,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":52348,"kind":"person","name":"Calvin Sandra","position":1,"cik":"0001882909","reported_name":"Calvin Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF ACCOUNTING OFFICER"}}],"security":"Common Stock","published_at":"2025-12-16T21:23:09.000Z","date":"2025-12-15","kind":"sale","planned":true,"acquired":false,"shares":2910,"price":36,"value":104760.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was made pursuant to a written plan adopted on June 10, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."}],"balance_after":45635,"source":{"system":"sec-edgar","filing":"0001882909-25-000006","document":"form4-12162025_091205.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1882909/000188290925000006/form4-12162025_091205.xml","form_type":"4"}},{"id":1006246,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":52348,"kind":"person","name":"Calvin Sandra","position":1,"cik":"0001882909","reported_name":"Calvin Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF ACCOUNTING OFFICER"}}],"security":"Employee stock option (right to buy)","published_at":"2025-11-06T21:05:05.000Z","date":"2025-11-04","kind":"exercise","planned":true,"acquired":false,"shares":6250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"One-fourth of the shares subject to the stock option vested and became exercisable on the first anniversary of January 31, 2024, and the remaining shares vest in 36 equal monthly installments thereafter."}],"balance_after":18750,"derivative":{"exercise_price":8.93,"expiration_date":"2034-01-31","underlying":"Common Stock","underlying_shares":6250},"source":{"system":"sec-edgar","filing":"0001882909-25-000004","document":"form4-11062025_041101.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1882909/000188290925000004/form4-11062025_041101.xml","form_type":"4"}},{"id":1006245,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":52348,"kind":"person","name":"Calvin Sandra","position":1,"cik":"0001882909","reported_name":"Calvin Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF ACCOUNTING OFFICER"}}],"security":"Employee stock option (right to buy)","published_at":"2025-11-06T21:05:05.000Z","date":"2025-11-04","kind":"exercise","planned":true,"acquired":false,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"One-fourth of the shares subject to the stock option vested and became exercisable on the first anniversary of January 31, 2023, and the remaining shares vest in 36 equal monthly installments thereafter."}],"balance_after":7500,"derivative":{"exercise_price":22.4,"expiration_date":"2033-01-31","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001882909-25-000004","document":"form4-11062025_041101.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1882909/000188290925000004/form4-11062025_041101.xml","form_type":"4"}},{"id":1006244,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":52348,"kind":"person","name":"Calvin Sandra","position":1,"cik":"0001882909","reported_name":"Calvin Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF ACCOUNTING OFFICER"}}],"security":"Employee stock option (right to buy)","published_at":"2025-11-06T21:05:05.000Z","date":"2025-11-04","kind":"exercise","planned":true,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One-fourth of the shares subject to the stock option vested and became exercisable on the first anniversary of January 31, 2022, and the remaining shares vest in 36 equal monthly installments thereafter."}],"balance_after":2500,"derivative":{"exercise_price":27.5,"expiration_date":"2032-01-31","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001882909-25-000004","document":"form4-11062025_041101.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1882909/000188290925000004/form4-11062025_041101.xml","form_type":"4"}},{"id":1006243,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":52348,"kind":"person","name":"Calvin Sandra","position":1,"cik":"0001882909","reported_name":"Calvin Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF ACCOUNTING OFFICER"}}],"security":"Employee stock option (right to buy)","published_at":"2025-11-06T21:05:05.000Z","date":"2025-11-04","kind":"exercise","planned":true,"acquired":false,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":26.88,"expiration_date":"2031-01-21","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001882909-25-000004","document":"form4-11062025_041101.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1882909/000188290925000004/form4-11062025_041101.xml","form_type":"4"}},{"id":1006242,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":52348,"kind":"person","name":"Calvin Sandra","position":1,"cik":"0001882909","reported_name":"Calvin Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF ACCOUNTING OFFICER"}}],"security":"Employee stock option (right to buy)","published_at":"2025-11-06T21:05:05.000Z","date":"2025-11-04","kind":"exercise","planned":true,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":25.25,"expiration_date":"2028-05-10","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001882909-25-000004","document":"form4-11062025_041101.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1882909/000188290925000004/form4-11062025_041101.xml","form_type":"4"}},{"id":1006241,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":52348,"kind":"person","name":"Calvin Sandra","position":1,"cik":"0001882909","reported_name":"Calvin Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF ACCOUNTING OFFICER"}}],"security":"Common Stock","published_at":"2025-11-06T21:05:05.000Z","date":"2025-11-04","kind":"sale","planned":true,"acquired":false,"shares":67115,"price":36,"value":2416140.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was made pursuant to a written plan adopted on June 10, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."}],"balance_after":48545,"source":{"system":"sec-edgar","filing":"0001882909-25-000004","document":"form4-11062025_041101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1882909/000188290925000004/form4-11062025_041101.xml","form_type":"4"}},{"id":1006240,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":52348,"kind":"person","name":"Calvin Sandra","position":1,"cik":"0001882909","reported_name":"Calvin Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF ACCOUNTING OFFICER"}}],"security":"Common Stock","published_at":"2025-11-06T21:05:05.000Z","date":"2025-11-04","kind":"exercise","planned":true,"acquired":true,"shares":6250,"price":8.93,"value":55812.5,"ownership":{"direct":true},"balance_after":115660,"source":{"system":"sec-edgar","filing":"0001882909-25-000004","document":"form4-11062025_041101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1882909/000188290925000004/form4-11062025_041101.xml","form_type":"4"}},{"id":1006239,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":52348,"kind":"person","name":"Calvin Sandra","position":1,"cik":"0001882909","reported_name":"Calvin Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF ACCOUNTING OFFICER"}}],"security":"Common Stock","published_at":"2025-11-06T21:05:05.000Z","date":"2025-11-04","kind":"exercise","planned":true,"acquired":true,"shares":12500,"price":22.4,"value":280000.0,"ownership":{"direct":true},"balance_after":109410,"source":{"system":"sec-edgar","filing":"0001882909-25-000004","document":"form4-11062025_041101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1882909/000188290925000004/form4-11062025_041101.xml","form_type":"4"}},{"id":1006238,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":52348,"kind":"person","name":"Calvin Sandra","position":1,"cik":"0001882909","reported_name":"Calvin Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF ACCOUNTING OFFICER"}}],"security":"Common Stock","published_at":"2025-11-06T21:05:05.000Z","date":"2025-11-04","kind":"exercise","planned":true,"acquired":true,"shares":15000,"price":27.5,"value":412500.0,"ownership":{"direct":true},"balance_after":96910,"source":{"system":"sec-edgar","filing":"0001882909-25-000004","document":"form4-11062025_041101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1882909/000188290925000004/form4-11062025_041101.xml","form_type":"4"}},{"id":1006237,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":52348,"kind":"person","name":"Calvin Sandra","position":1,"cik":"0001882909","reported_name":"Calvin Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF ACCOUNTING OFFICER"}}],"security":"Common Stock","published_at":"2025-11-06T21:05:05.000Z","date":"2025-11-04","kind":"exercise","planned":true,"acquired":true,"shares":17500,"price":26.88,"value":470400.0,"ownership":{"direct":true},"balance_after":81910,"source":{"system":"sec-edgar","filing":"0001882909-25-000004","document":"form4-11062025_041101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1882909/000188290925000004/form4-11062025_041101.xml","form_type":"4"}},{"id":1006236,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":52348,"kind":"person","name":"Calvin Sandra","position":1,"cik":"0001882909","reported_name":"Calvin Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF ACCOUNTING OFFICER"}}],"security":"Common Stock","published_at":"2025-11-06T21:05:05.000Z","date":"2025-11-04","kind":"exercise","planned":true,"acquired":true,"shares":10000,"price":25.25,"value":252500.0,"ownership":{"direct":true},"balance_after":64410,"source":{"system":"sec-edgar","filing":"0001882909-25-000004","document":"form4-11062025_041101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1882909/000188290925000004/form4-11062025_041101.xml","form_type":"4"}},{"id":1272529,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":52348,"kind":"person","name":"Calvin Sandra","position":1,"cik":"0001882909","reported_name":"Calvin Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF ACCOUNTING OFFICER"}}],"security":"Employee stock option (right to buy)","published_at":"2025-02-13T02:27:02.000Z","date":"2025-02-11","kind":"exercise","planned":true,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The stock option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":15.46,"expiration_date":"2030-01-31","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001415889-25-003822","document":"form4-02132025_020258.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1882909/000141588925003822/form4-02132025_020258.xml","form_type":"4"}},{"id":1272528,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":52348,"kind":"person","name":"Calvin Sandra","position":1,"cik":"0001882909","reported_name":"Calvin Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF ACCOUNTING OFFICER"}}],"security":"Employee stock option (right to buy)","published_at":"2025-02-13T02:27:02.000Z","date":"2025-02-11","kind":"exercise","planned":true,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The stock option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":17.96,"expiration_date":"2029-05-09","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001415889-25-003822","document":"form4-02132025_020258.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1882909/000141588925003822/form4-02132025_020258.xml","form_type":"4"}},{"id":1272527,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":52348,"kind":"person","name":"Calvin Sandra","position":1,"cik":"0001882909","reported_name":"Calvin Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF ACCOUNTING OFFICER"}}],"security":"Employee stock option (right to buy)","published_at":"2025-02-13T02:27:02.000Z","date":"2025-02-11","kind":"exercise","planned":true,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The stock option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":17.44,"expiration_date":"2027-05-17","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001415889-25-003822","document":"form4-02132025_020258.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1882909/000141588925003822/form4-02132025_020258.xml","form_type":"4"}},{"id":1272526,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":52348,"kind":"person","name":"Calvin Sandra","position":1,"cik":"0001882909","reported_name":"Calvin Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF ACCOUNTING OFFICER"}}],"security":"Employee stock option (right to buy)","published_at":"2025-02-13T02:27:02.000Z","date":"2025-02-11","kind":"exercise","planned":true,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The stock option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":16.23,"expiration_date":"2026-05-19","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001415889-25-003822","document":"form4-02132025_020258.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1882909/000141588925003822/form4-02132025_020258.xml","form_type":"4"}},{"id":1272525,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":52348,"kind":"person","name":"Calvin Sandra","position":1,"cik":"0001882909","reported_name":"Calvin Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF ACCOUNTING OFFICER"}}],"security":"Common Stock","published_at":"2025-02-13T02:27:02.000Z","date":"2025-02-11","kind":"sale","planned":true,"acquired":false,"shares":9244,"price":25,"value":231100.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"This sale was made pursuant to a written plan adopted on September 9, 2024, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."}],"balance_after":54410,"source":{"system":"sec-edgar","filing":"0001415889-25-003822","document":"form4-02132025_020258.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1882909/000141588925003822/form4-02132025_020258.xml","form_type":"4"}},{"id":1272524,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":52348,"kind":"person","name":"Calvin Sandra","position":1,"cik":"0001882909","reported_name":"Calvin Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF ACCOUNTING OFFICER"}}],"security":"Common Stock","published_at":"2025-02-13T02:27:02.000Z","date":"2025-02-11","kind":"sale","planned":true,"acquired":false,"shares":15000,"price":25,"value":375000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"This sale was made pursuant to a written plan adopted on September 9, 2024, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option grant to the Reporting Person on January 31, 2020 with an expiration date of  January 31, 2030."}],"balance_after":63654,"source":{"system":"sec-edgar","filing":"0001415889-25-003822","document":"form4-02132025_020258.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1882909/000141588925003822/form4-02132025_020258.xml","form_type":"4"}},{"id":1272523,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":52348,"kind":"person","name":"Calvin Sandra","position":1,"cik":"0001882909","reported_name":"Calvin Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF ACCOUNTING OFFICER"}}],"security":"Common Stock","published_at":"2025-02-13T02:27:02.000Z","date":"2025-02-11","kind":"exercise","planned":true,"acquired":true,"shares":15000,"price":15.46,"value":231900.0,"ownership":{"direct":true},"balance_after":78654,"source":{"system":"sec-edgar","filing":"0001415889-25-003822","document":"form4-02132025_020258.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1882909/000141588925003822/form4-02132025_020258.xml","form_type":"4"}},{"id":1272522,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":52348,"kind":"person","name":"Calvin Sandra","position":1,"cik":"0001882909","reported_name":"Calvin Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF ACCOUNTING OFFICER"}}],"security":"Common Stock","published_at":"2025-02-13T02:27:02.000Z","date":"2025-02-11","kind":"sale","planned":true,"acquired":false,"shares":10000,"price":25,"value":250000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"This sale was made pursuant to a written plan adopted on September 9, 2024, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option grant to the Reporting Person on May 9, 2019 with an expiration date of  May 9, 2029."}],"balance_after":63654,"source":{"system":"sec-edgar","filing":"0001415889-25-003822","document":"form4-02132025_020258.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1882909/000141588925003822/form4-02132025_020258.xml","form_type":"4"}},{"id":1272521,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":52348,"kind":"person","name":"Calvin Sandra","position":1,"cik":"0001882909","reported_name":"Calvin Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF ACCOUNTING OFFICER"}}],"security":"Common Stock","published_at":"2025-02-13T02:27:02.000Z","date":"2025-02-11","kind":"exercise","planned":true,"acquired":true,"shares":10000,"price":17.96,"value":179600.0,"ownership":{"direct":true},"balance_after":73654,"source":{"system":"sec-edgar","filing":"0001415889-25-003822","document":"form4-02132025_020258.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1882909/000141588925003822/form4-02132025_020258.xml","form_type":"4"}},{"id":1272520,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":52348,"kind":"person","name":"Calvin Sandra","position":1,"cik":"0001882909","reported_name":"Calvin Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF ACCOUNTING OFFICER"}}],"security":"Common Stock","published_at":"2025-02-13T02:27:02.000Z","date":"2025-02-11","kind":"sale","planned":true,"acquired":false,"shares":10000,"price":25,"value":250000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was made pursuant to a written plan adopted on September 9, 2024, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option grant to the Reporting Person on May 17, 2017 with an expiration date of  May 17, 2027."}],"balance_after":63654,"source":{"system":"sec-edgar","filing":"0001415889-25-003822","document":"form4-02132025_020258.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1882909/000141588925003822/form4-02132025_020258.xml","form_type":"4"}},{"id":1272519,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":52348,"kind":"person","name":"Calvin Sandra","position":1,"cik":"0001882909","reported_name":"Calvin Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF ACCOUNTING OFFICER"}}],"security":"Common Stock","published_at":"2025-02-13T02:27:02.000Z","date":"2025-02-11","kind":"exercise","planned":true,"acquired":true,"shares":10000,"price":17.44,"value":174400.0,"ownership":{"direct":true},"balance_after":73654,"source":{"system":"sec-edgar","filing":"0001415889-25-003822","document":"form4-02132025_020258.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1882909/000141588925003822/form4-02132025_020258.xml","form_type":"4"}},{"id":1272518,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":52348,"kind":"person","name":"Calvin Sandra","position":1,"cik":"0001882909","reported_name":"Calvin Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF ACCOUNTING OFFICER"}}],"security":"Common Stock","published_at":"2025-02-13T02:27:02.000Z","date":"2025-02-11","kind":"sale","planned":true,"acquired":false,"shares":10000,"price":25,"value":250000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was made pursuant to a written plan adopted on September 9, 2024, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option grant to the Reporting Person on May 19, 2016 with an expiration date of  May 19, 2026."}],"balance_after":63654,"source":{"system":"sec-edgar","filing":"0001415889-25-003822","document":"form4-02132025_020258.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1882909/000141588925003822/form4-02132025_020258.xml","form_type":"4"}},{"id":1272517,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":52348,"kind":"person","name":"Calvin Sandra","position":1,"cik":"0001882909","reported_name":"Calvin Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF ACCOUNTING OFFICER"}}],"security":"Common Stock","published_at":"2025-02-13T02:27:02.000Z","date":"2025-02-11","kind":"exercise","planned":true,"acquired":true,"shares":10000,"price":16.23,"value":162300.0,"ownership":{"direct":true},"balance_after":73654,"source":{"system":"sec-edgar","filing":"0001415889-25-003822","document":"form4-02132025_020258.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1882909/000141588925003822/form4-02132025_020258.xml","form_type":"4"}},{"id":1286138,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":52348,"kind":"person","name":"Calvin Sandra","position":1,"cik":"0001882909","reported_name":"Calvin Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF ACCOUNTING OFFICER"}}],"security":"Employee stock option (right to buy)","published_at":"2025-02-05T01:30:07.000Z","date":"2025-01-31","kind":"grant","planned":false,"acquired":true,"shares":26000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter."}],"balance_after":26000,"derivative":{"exercise_price":20.46,"expiration_date":"2035-01-31","underlying":"Common Stock","underlying_shares":26000},"source":{"system":"sec-edgar","filing":"0001415889-25-003061","document":"form4-02042025_080201.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1882909/000141588925003061/form4-02042025_080201.xml","form_type":"4"}},{"id":1286137,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":52348,"kind":"person","name":"Calvin Sandra","position":1,"cik":"0001882909","reported_name":"Calvin Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF ACCOUNTING OFFICER"}}],"security":"Common Stock","published_at":"2025-02-05T01:30:07.000Z","date":"2025-02-03","kind":"sale","planned":false,"acquired":false,"shares":3348,"price":20.12,"value":67361.76,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a \"sell to cover\" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person."}],"balance_after":63654,"source":{"system":"sec-edgar","filing":"0001415889-25-003061","document":"form4-02042025_080201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1882909/000141588925003061/form4-02042025_080201.xml","form_type":"4"}},{"id":1286136,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":52348,"kind":"person","name":"Calvin Sandra","position":1,"cik":"0001882909","reported_name":"Calvin Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF ACCOUNTING OFFICER"}}],"security":"Common Stock","published_at":"2025-02-05T01:30:07.000Z","date":"2025-01-31","kind":"grant","planned":false,"acquired":true,"shares":13000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer."}],"balance_after":67002,"source":{"system":"sec-edgar","filing":"0001415889-25-003061","document":"form4-02042025_080201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1882909/000141588925003061/form4-02042025_080201.xml","form_type":"4"}},{"id":1296987,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":52348,"kind":"person","name":"Calvin Sandra","position":1,"cik":"0001882909","reported_name":"Calvin Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF ACCOUNTING OFFICER"}}],"security":"Common Stock","published_at":"2025-01-24T01:31:02.000Z","date":"2025-01-22","kind":"sale","planned":false,"acquired":false,"shares":925,"price":18.9408,"value":17520.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a \"sell to cover\" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person."}],"balance_after":54002,"source":{"system":"sec-edgar","filing":"0001415889-25-001997","document":"form4-01242025_010158.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1882909/000141588925001997/form4-01242025_010158.xml","form_type":"4"}},{"id":1321156,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":52348,"kind":"person","name":"Calvin Sandra","position":1,"cik":"0001882909","reported_name":"Calvin Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF ACCOUNTING OFFICER"}}],"security":"Employee stock option (right to buy)","published_at":"2024-12-28T00:47:04.000Z","date":"2024-12-26","kind":"exercise","planned":true,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":12.67,"expiration_date":"2025-01-02","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001415889-24-030210","document":"form4-12282024_121201.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1882909/000141588924030210/form4-12282024_121201.xml","form_type":"4"}},{"id":1321155,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":52348,"kind":"person","name":"Calvin Sandra","position":1,"cik":"0001882909","reported_name":"Calvin Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF ACCOUNTING OFFICER"}}],"security":"Common Stock","published_at":"2024-12-28T00:47:04.000Z","date":"2024-12-26","kind":"sale","planned":true,"acquired":false,"shares":15000,"price":17.2185,"value":258277.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, adopted by the Reporting Person on September 9, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $17.21856, and the range of prices were between $16.985 and $17.545. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided."}],"balance_after":54927,"source":{"system":"sec-edgar","filing":"0001415889-24-030210","document":"form4-12282024_121201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1882909/000141588924030210/form4-12282024_121201.xml","form_type":"4"}},{"id":1321154,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":52348,"kind":"person","name":"Calvin Sandra","position":1,"cik":"0001882909","reported_name":"Calvin Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF ACCOUNTING OFFICER"}}],"security":"Common Stock","published_at":"2024-12-28T00:47:04.000Z","date":"2024-12-26","kind":"exercise","planned":true,"acquired":true,"shares":15000,"price":12.67,"value":190050.0,"ownership":{"direct":true},"balance_after":69927,"source":{"system":"sec-edgar","filing":"0001415889-24-030210","document":"form4-12282024_121201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1882909/000141588924030210/form4-12282024_121201.xml","form_type":"4"}},{"id":1353351,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":52348,"kind":"person","name":"Calvin Sandra","position":1,"cik":"0001882909","reported_name":"Calvin Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF ACCOUNTING OFFICER"}}],"security":"Employee stock option (right to buy)","published_at":"2024-11-26T02:00:49.000Z","date":"2024-11-25","kind":"exercise","planned":false,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option is fully vested and exercisable."}],"balance_after":15000,"derivative":{"exercise_price":12.67,"expiration_date":"2025-01-02","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001415889-24-027672","document":"form4-11262024_021145.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1882909/000141588924027672/form4-11262024_021145.xml","form_type":"4"}},{"id":1353350,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":52348,"kind":"person","name":"Calvin Sandra","position":1,"cik":"0001882909","reported_name":"Calvin Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF ACCOUNTING OFFICER"}}],"security":"Common Stock","published_at":"2024-11-26T02:00:49.000Z","date":"2024-11-25","kind":"sale","planned":false,"acquired":false,"shares":12090,"price":18.3009,"value":221257.881,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the Reporting Person in order to cover the tax withholding obligation and payment of the exercise price in connection with the  partial exercise of a stock option granted to the Reporting Person on January 2, 2015 with an upcoming expiration date of January 2, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $18.3009, and the range of prices were between $18.27 and $18.37. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided."}],"balance_after":54927,"source":{"system":"sec-edgar","filing":"0001415889-24-027672","document":"form4-11262024_021145.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1882909/000141588924027672/form4-11262024_021145.xml","form_type":"4"}},{"id":1353349,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":52348,"kind":"person","name":"Calvin Sandra","position":1,"cik":"0001882909","reported_name":"Calvin Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF ACCOUNTING OFFICER"}}],"security":"Common Stock","published_at":"2024-11-26T02:00:49.000Z","date":"2024-11-25","kind":"exercise","planned":false,"acquired":true,"shares":15000,"price":12.67,"value":190050.0,"ownership":{"direct":true},"balance_after":67017,"source":{"system":"sec-edgar","filing":"0001415889-24-027672","document":"form4-11262024_021145.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1882909/000141588924027672/form4-11262024_021145.xml","form_type":"4"}},{"id":1662832,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":52348,"kind":"person","name":"Calvin Sandra","position":1,"cik":"0001882909","reported_name":"Calvin Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF ACCOUNTING OFFICER"}}],"security":"Employee stock option (right to buy)","published_at":"2024-02-02T21:05:37.000Z","date":"2024-01-31","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter."}],"balance_after":25000,"derivative":{"exercise_price":8.93,"expiration_date":"2034-01-30","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001415889-24-002279","document":"form4-02022024_040202.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1882909/000141588924002279/form4-02022024_040202.xml","form_type":"4"}},{"id":1662831,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":52348,"kind":"person","name":"Calvin Sandra","position":1,"cik":"0001882909","reported_name":"Calvin Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF ACCOUNTING OFFICER"}}],"security":"Common Stock","published_at":"2024-02-02T21:05:37.000Z","date":"2024-02-01","kind":"sale","planned":false,"acquired":false,"shares":2820,"price":8.5312,"value":24057.984,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a \"sell to cover\" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The weighted average sale price for the reported transaction was $8.5312, and the range of prices were between $8.5309 and $8.5315.  Upon request by the SEC staff, the Issuer or any securityholder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":52017,"source":{"system":"sec-edgar","filing":"0001415889-24-002279","document":"form4-02022024_040202.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1882909/000141588924002279/form4-02022024_040202.xml","form_type":"4"}},{"id":1662830,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":52348,"kind":"person","name":"Calvin Sandra","position":1,"cik":"0001882909","reported_name":"Calvin Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF ACCOUNTING OFFICER"}}],"security":"Common Stock","published_at":"2024-02-02T21:05:37.000Z","date":"2024-01-31","kind":"grant","planned":false,"acquired":true,"shares":1000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer."}],"balance_after":54837,"source":{"system":"sec-edgar","filing":"0001415889-24-002279","document":"form4-02022024_040202.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1882909/000141588924002279/form4-02022024_040202.xml","form_type":"4"}},{"id":1662829,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":52348,"kind":"person","name":"Calvin Sandra","position":1,"cik":"0001882909","reported_name":"Calvin Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF ACCOUNTING OFFICER"}}],"security":"Common Stock","published_at":"2024-02-02T21:05:37.000Z","date":"2024-01-31","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer."}],"balance_after":53837,"source":{"system":"sec-edgar","filing":"0001415889-24-002279","document":"form4-02022024_040202.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1882909/000141588924002279/form4-02022024_040202.xml","form_type":"4"}},{"id":1671408,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":52348,"kind":"person","name":"Calvin Sandra","position":1,"cik":"0001882909","reported_name":"Calvin Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF ACCOUNTING OFFICER"}}],"security":"Common Stock","published_at":"2024-01-25T21:10:12.000Z","date":"2024-01-23","kind":"sale","planned":false,"acquired":false,"shares":910,"price":9.0684,"value":8252.244,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a \"sell to cover\" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person."}],"balance_after":41337,"source":{"system":"sec-edgar","filing":"0001415889-24-001796","document":"form4-01252024_040102.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1882909/000141588924001796/form4-01252024_040102.xml","form_type":"4"}},{"id":1895774,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":52348,"kind":"person","name":"Calvin Sandra","position":1,"cik":"0001882909","reported_name":"Calvin Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2023-05-12T20:06:20.000Z","date":"2023-05-11","kind":"sale","planned":true,"acquired":false,"shares":122,"price":16.12,"value":1966.64,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were made pursuant to a written plan adopted by the Reporting Person on September 14, 2022 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units."}],"balance_after":42247,"source":{"system":"sec-edgar","filing":"0001209191-23-028993","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1882909/000120919123028993/doc4.xml","form_type":"4"}},{"id":1895773,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":52348,"kind":"person","name":"Calvin Sandra","position":1,"cik":"0001882909","reported_name":"Calvin Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2023-05-12T20:06:20.000Z","date":"2023-05-10","kind":"sale","planned":true,"acquired":false,"shares":436,"price":16.59,"value":7233.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a \"sell to cover\" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person."}],"balance_after":42369,"source":{"system":"sec-edgar","filing":"0001209191-23-028993","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1882909/000120919123028993/doc4.xml","form_type":"4"}},{"id":2037238,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":52348,"kind":"person","name":"Calvin Sandra","position":1,"cik":"0001882909","reported_name":"Calvin Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Accounting Officer"}}],"security":"Employee stock option (right to buy)","published_at":"2023-02-02T23:53:33.000Z","date":"2023-01-31","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter."}],"balance_after":20000,"derivative":{"exercise_price":22.4,"expiration_date":"2033-01-30","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-23-006413","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1882909/000120919123006413/doc4.xml","form_type":"4"}},{"id":2037237,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":52348,"kind":"person","name":"Calvin Sandra","position":1,"cik":"0001882909","reported_name":"Calvin Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2023-02-02T23:53:33.000Z","date":"2023-02-02","kind":"sale","acquired":false,"shares":360,"price":22.42,"value":8071.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units."}],"balance_after":42805,"source":{"system":"sec-edgar","filing":"0001209191-23-006413","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1882909/000120919123006413/doc4.xml","form_type":"4"}},{"id":2037236,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":52348,"kind":"person","name":"Calvin Sandra","position":1,"cik":"0001882909","reported_name":"Calvin Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2023-02-02T23:53:33.000Z","date":"2023-02-01","kind":"sale","acquired":false,"shares":1671,"price":21.752,"value":36347.592,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a \"sell to cover\" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person."}],"balance_after":43165,"source":{"system":"sec-edgar","filing":"0001209191-23-006413","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1882909/000120919123006413/doc4.xml","form_type":"4"}},{"id":2037235,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":52348,"kind":"person","name":"Calvin Sandra","position":1,"cik":"0001882909","reported_name":"Calvin Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2023-02-02T23:53:33.000Z","date":"2023-01-31","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer."}],"balance_after":44836,"source":{"system":"sec-edgar","filing":"0001209191-23-006413","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1882909/000120919123006413/doc4.xml","form_type":"4"}},{"id":2045638,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":52348,"kind":"person","name":"Calvin Sandra","position":1,"cik":"0001882909","reported_name":"Calvin Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2023-01-26T21:05:49.000Z","date":"2023-01-25","kind":"sale","acquired":false,"shares":192,"price":21.63,"value":4152.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units."}],"balance_after":34836,"source":{"system":"sec-edgar","filing":"0001209191-23-005037","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1882909/000120919123005037/doc4.xml","form_type":"4"}},{"id":2045637,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":52348,"kind":"person","name":"Calvin Sandra","position":1,"cik":"0001882909","reported_name":"Calvin Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2023-01-26T21:05:49.000Z","date":"2023-01-24","kind":"sale","acquired":false,"shares":905,"price":21.9044,"value":19823.482,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a \"sell to cover\" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person."}],"balance_after":35028,"source":{"system":"sec-edgar","filing":"0001209191-23-005037","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1882909/000120919123005037/doc4.xml","form_type":"4"}},{"id":2158829,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":52348,"kind":"person","name":"Calvin Sandra","position":1,"cik":"0001882909","reported_name":"Calvin Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2022-09-15T20:05:11.000Z","date":"2022-09-13","kind":"sale","acquired":false,"shares":349,"price":28,"value":9772.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a \"sell to cover\" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 549 shares of the Issuer's common stock acquired by the reporting person on May 31, 2022 pursuant to an employee stock purchase program."}],"balance_after":35933,"source":{"system":"sec-edgar","filing":"0001209191-22-050038","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1882909/000120919122050038/doc4.xml","form_type":"4"}},{"id":2274109,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":52348,"kind":"person","name":"Calvin Sandra","position":1,"cik":"0001882909","reported_name":"Calvin Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2022-05-13T00:44:15.000Z","date":"2022-05-11","kind":"sale","acquired":false,"shares":445,"price":21.9235,"value":9755.9575,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a \"sell to cover\" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person."}],"balance_after":35733,"source":{"system":"sec-edgar","filing":"0001209191-22-028706","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1882909/000120919122028706/doc4.xml","form_type":"4"}},{"id":2274108,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":52348,"kind":"person","name":"Calvin Sandra","position":1,"cik":"0001882909","reported_name":"Calvin Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2022-05-13T00:44:15.000Z","date":"2022-05-10","kind":"sale","acquired":false,"shares":436,"price":21.51,"value":9378.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a \"sell to cover\" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person."}],"balance_after":36178,"source":{"system":"sec-edgar","filing":"0001209191-22-028706","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1882909/000120919122028706/doc4.xml","form_type":"4"}},{"id":2417688,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":52348,"kind":"person","name":"Calvin Sandra","position":1,"cik":"0001882909","reported_name":"Calvin Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Corp Controller and CAO"}}],"security":"Employee stock option (right to buy)","published_at":"2022-02-02T21:22:19.000Z","date":"2022-01-31","kind":"grant","acquired":true,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter."}],"balance_after":17500,"derivative":{"exercise_price":27.5,"expiration_date":"2032-01-30","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001209191-22-006372","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1882909/000120919122006372/doc4.xml","form_type":"4"}},{"id":2417687,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":52348,"kind":"person","name":"Calvin Sandra","position":1,"cik":"0001882909","reported_name":"Calvin Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Corp Controller and CAO"}}],"security":"Common Stock","published_at":"2022-02-02T21:22:19.000Z","date":"2022-01-31","kind":"sale","acquired":false,"shares":798,"price":26.5059,"value":21151.7082,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a \"sell to cover\" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person."}],"balance_after":36614,"source":{"system":"sec-edgar","filing":"0001209191-22-006372","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1882909/000120919122006372/doc4.xml","form_type":"4"}},{"id":2417686,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":52348,"kind":"person","name":"Calvin Sandra","position":1,"cik":"0001882909","reported_name":"Calvin Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Corp Controller and CAO"}}],"security":"Common Stock","published_at":"2022-02-02T21:22:19.000Z","date":"2022-01-31","kind":"grant","acquired":true,"shares":8750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan that are scheduled to vest over four years."}],"balance_after":37412,"source":{"system":"sec-edgar","filing":"0001209191-22-006372","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1882909/000120919122006372/doc4.xml","form_type":"4"}},{"id":2425627,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":52348,"kind":"person","name":"Calvin Sandra","position":1,"cik":"0001882909","reported_name":"Calvin Sandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Corp Controller and CAO"}}],"security":"Common Stock","published_at":"2022-01-26T21:38:39.000Z","date":"2022-01-24","kind":"sale","acquired":false,"shares":934,"price":24.5767,"value":22954.6378,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a \"sell to cover\" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 842 shares of the Issuer's common stock acquired by the reporting person on November 30, 2021 pursuant to an employee stock purchase program."}],"balance_after":28662,"source":{"system":"sec-edgar","filing":"0001209191-22-005084","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1882909/000120919122005084/doc4.xml","form_type":"4"}}]}